Vivid stories help NPS' Natpara win panel support
This article was originally published in Scrip
Executive Summary
It was apparent at the FDA's 12 September meeting of the agency's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) the vivid descriptions patients relayed about the adverse effects they confront on a frequent, sometimes daily, basis in dealing with hypoparathyroidism strongly influenced the panel's ultimate 8-5 vote backing US approval of NPS Pharmaceuticals' Natpara, an injectable recombinant human parathyroid hormone replacement therapy.